AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9195083 — intervention group
Group type: COMPARATOR
Intervention: Nystatin (500,000 U four times daily for 14 days)
Number of subjects: 167
Study 9195083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 167
Study 9195083 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 167
Study 7808022 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoids and carotenoids as chemopreventive agents
Number of subjects: 0
Study 7808022 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3585412 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with OK-432 combined with chemotherapy
Number of subjects: 311
Study 3585412 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control group)
Number of subjects: 311
Study 31906881 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received two 60-90 min group breastfeeding educational sessions based on the breastfeeding self-efficacy theory along with routine care.
Number of subjects: 130
Study 31906881 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastfeeding in both experimental and control groups.
Number of subjects: 130
Study 29745884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 4 and 8 mg/kg in combination with methotrexate (MTX)
Number of subjects: 904
Study 29745884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 904
Study 29745884 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) plus placebo
Number of subjects: 904
Study 26469809 — intervention group
Group type: EXPERIMENTAL
Intervention: Test toothpaste containing 0.6% Cortex Ilicis Rotundae
Number of subjects: 100
Study 26469809 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste without any active ingredient
Number of subjects: 100
Study 25538197 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 127
Study 25538197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 24129362 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive dehydration (PAS)
Number of subjects: 23
Study 24129362 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dehydration (ACT)
Number of subjects: 23
Study 20971512 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg escitalopram
Number of subjects: 20
Study 20971512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17713346 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy (2 mg daily)
Number of subjects: 45
Study 17713346 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estrogen therapy (0.05 mg daily)
Number of subjects: 45
Study 17035408 — intervention group
Group type: COMPARATOR
Intervention: Obesity (BMI >= 30)
Number of subjects: 10258
Study 17035408 — intervention group
Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 10258
Study 12597081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (2.5 mmol/L)
Number of subjects: 16
Study 12597081 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (4.5 mmol/L)
Number of subjects: 16
Study 10910840 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine 3 mg followed by succinylcholine 1.5 mg/kg
Number of subjects: 119
Study 10910840 — intervention group
Group type: COMPARATOR
Intervention: mivacurium 0.2 mg/kg
Number of subjects: 119
Study 8659780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1, 3, and 6 mg.min(‐1))
Number of subjects: 9
Study 8659780 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25, 0.75, and 1.5 mg.min(‐1))
Number of subjects: 9
Study 8659780 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 9
Study 1404502 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate resuscitation (IV fluid resuscitation initiated in the ambulance and emergency center before surgical intervention)
Number of subjects: 300
Study 1404502 — intervention group
Group type: COMPARATOR
Intervention: Delayed resuscitation (IV fluid resuscitation delayed until surgical intervention)
Number of subjects: 300
Study 1404502 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate resuscitation
Number of subjects: 300
Study 1404502 — intervention group
Group type: COMPARATOR
Intervention: Delayed resuscitation
Number of subjects: 300
Study 3620276 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam (300 mg day-1)
Number of subjects: 40
Study 3620276 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (40 mg day-1 for the first two days and 20 mg day-1 for the remaining days)
Number of subjects: 40
Study 3620276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both isoxicam and piroxicam
Number of subjects: 40
Study 30040774 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable surface group
Number of subjects: 24
Study 30040774 — intervention group
Group type: COMPARATOR
Intervention: Stable surface group
Number of subjects: 24
Study 30040774 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 27298410 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) + ipilimumab
Number of subjects: 19
Study 25015174 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-6000
Number of subjects: 36
Study 22240725 — intervention group
Group type: EXPERIMENTAL
Intervention: The Biggest Loser (one episode)
Number of subjects: 59
Study 22240725 — intervention group
Group type: COMPARATOR
Intervention: Nature reality show (one episode)
Number of subjects: 59
Study 21095267 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 16064
Study 21095267 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombins
Number of subjects: 16064
Study 21095267 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa antagonists
Number of subjects: 16064
Study 21095267 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 16064
Study 21095267 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 16064
Study 18702962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest waist-to-height ratio (WHtR <0.45) in men
Number of subjects: 49032
Study 18702962 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest waist-to-height ratio (WHtR >=0.69) in men
Number of subjects: 49032
Study 18702962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest waist-to-height ratio (WHtR <0.42) in women
Number of subjects: 49032
Study 18702962 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest waist-to-height ratio (WHtR >=0.68) in women
Number of subjects: 49032
Study 15897165 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05%
Number of subjects: 151
Study 15897165 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol solution 0.005%
Number of subjects: 151
Study 12892806 — intervention group
Group type: EXPERIMENTAL
Intervention: BioGlue (BioGlue Surgical Adhesive; CryoLife, Inc)
Number of subjects: 151
Study 12892806 — intervention group
Group type: COMPARATOR
Intervention: Standard repair alone (Control)
Number of subjects: 151
Study 12892806 — intervention group
Group type: EXPERIMENTAL
Intervention: BioGlue
Number of subjects: 151
Study 10847132 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplicor HCV Monitor test
Number of subjects: 133
Study 10847132 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantiplex HCV RNA 2.0 assay
Number of subjects: 133
Study 10847132 — intervention group
Group type: COMPARATOR
Intervention: Monitor test
Number of subjects: 133
Study 10847132 — intervention group
Group type: COMPARATOR
Intervention: Quantiplex assay
Number of subjects: 133
Study 10847132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both assays
Number of subjects: 133
Study 7851597 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrobeads test
Number of subjects: 125
Study 7851597 — intervention group
Group type: COMPARATOR
Intervention: Sperm Penetration Assay (SPA)
Number of subjects: 125
Study 1722697 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVmP + VB (cyclophosphamide, hydroxorubicin, VM26, prednisone, vincristine, and bleomycin)
Number of subjects: 141
Study 1722697 — intervention group
Group type: COMPARATOR
Intervention: CHVmP (cyclophosphamide, hydroxorubicin, VM26, prednisone)
Number of subjects: 141
Study 1722697 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVmP + VB
Number of subjects: 141
Study 1722697 — intervention group
Group type: COMPARATOR
Intervention: CHVmP
Number of subjects: 141
Study 6795663 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 1.2 mg
Number of subjects: 0
Study 6795663 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 10 mg
Number of subjects: 0
Study 6795663 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 31470886 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention aimed at enhancing the nutritional quality of meals served to young children, incorporating best practices from the Child and Adult Care Food Program.
Number of subjects: 52
Study 31470886 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental intervention aimed at increasing providers' environmental health literacy and self-efficacy for integrated pest management (IPM).
Number of subjects: 52
Study 31470886 — intervention group
Group type: COMPARATOR
Intervention: Matched attention control group receiving the same amount of attention (6 hours) and educational materials.
Number of subjects: 52
Study 28487444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab
Number of subjects: 132
Study 28487444 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 132
Study 28487444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab in estrogen receptor-positive patients
Number of subjects: 132
Study 28487444 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone in estrogen receptor-positive patients
Number of subjects: 132
Study 25869158 — intervention group
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 0
Study 23819631 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZM)
Number of subjects: 5000
Study 23819631 — intervention group
Group type: COMPARATOR
Intervention: ACE-inhibitor (ramipril)
Number of subjects: 5000
Study 21078948 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-488043 (AI) administered as monotherapy for 8 days
Number of subjects: 8
Study 21078948 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-488043 (AI)
Number of subjects: 8
Study 19506159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense temozolomide (150 mg/m² days 1 to 7 and 15 to 21)
Number of subjects: 85
Study 19506159 — intervention group
Group type: COMPARATOR
Intervention: Metronomic temozolomide (50 mg/m² continuous daily)
Number of subjects: 85
Study 17719618 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral caloric vestibular stimulation
Number of subjects: 0
Study 17719618 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15055895 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1% (0.25 mL) subcutaneously
Number of subjects: 301
Study 15055895 — intervention group
Group type: COMPARATOR
Intervention: No local anaesthesia
Number of subjects: 301
Study 15055895 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-G cannula with local anaesthesia
Number of subjects: 301
Study 15055895 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-G cannula with local anaesthesia
Number of subjects: 301
Study 15055895 — intervention group
Group type: COMPARATOR
Intervention: 14-G cannula without local anaesthesia
Number of subjects: 301
Study 15055895 — intervention group
Group type: COMPARATOR
Intervention: 16-G cannula without local anaesthesia
Number of subjects: 301
Study 12218703 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP)
Number of subjects: 8
Study 9660150 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise at 35%, 55%, and 75% of peak oxygen uptake for 5 minutes.
Number of subjects: 20
Study 9660150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise (30s cycling followed by 30s rest) for 3 minutes at the same resistance and cadence.
Number of subjects: 20
Study 9660150 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment of HR for climatic conditions using the equation HR(corr) = HR(meas) x (1.18308 - (0.0083218 x T(db))).
Number of subjects: 20
Study 8126244 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous oxygen irrigations (1 x a week for 8 weeks)
Number of subjects: 14
Study 8126244 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen irrigations (control)
Number of subjects: 14
Study 2929966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg by mouth the evening prior to surgery and 150 mg by mouth before the operation)
Number of subjects: 100
Study 2929966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (30 ml shortly before admission to the operating room)
Number of subjects: 100
Study 2929966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (30 ml via a separate gastric tube after the first pH measurement)
Number of subjects: 100
Study 2929966 — intervention group
Group type: COMPARATOR
Intervention: No premedication (22 patients)
Number of subjects: 100
Study 921869 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium administration
Number of subjects: 23
Study 31409158 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum LDL-C level in female patients
Number of subjects: 431
Study 30559004 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous (IV) infusion of LCB01-0371 at doses of 200, 400, 800, and 1200 mg
Number of subjects: 36
Study 30559004 — intervention group
Group type: COMPARATOR
Intervention: Single oral administration of LCB01-0371 at a dose of 800 mg
Number of subjects: 36
Study 30559004 — intervention group
Group type: COMPARATOR
Intervention: Single intravenous (IV) administration of LCB01-0371 at a dose of 400 mg
Number of subjects: 36
Study 30559004 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous (IV) administration of LCB01-0371
Number of subjects: 36
Study 28499730 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with silodosin 8 mg per day and dutasteride 0.5 mg per day for 12 months
Number of subjects: 140
Study 28499730 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride monotherapy after silodosin withdrawal
Number of subjects: 140
Study 25961616 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 30
Study 25961616 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 30
Study 23053688 — intervention group
Group type: EXPERIMENTAL
Intervention: Anbainuo plus MTX
Number of subjects: 396
Study 21684068 — intervention group
Group type: EXPERIMENTAL
Intervention: Single postoperative intravesical dose of mitomycin C (40 mg in 40 ml saline)
Number of subjects: 284
Study 21684068 — intervention group
Group type: COMPARATOR
Intervention: Standard management on removal of the urinary catheter
Number of subjects: 284
Study 20012785 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosalbutamol
Number of subjects: 60
Study 20012785 — intervention group
Group type: COMPARATOR
Intervention: Racemic salbutamol
Number of subjects: 60
Study 16397284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.01 mg
Number of subjects: 65
Study 16397284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.03 mg
Number of subjects: 65
Study 16397284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.1 mg
Number of subjects: 65
Study 16397284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.3 mg
Number of subjects: 65
Study 16397284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 1 mg
Number of subjects: 65
Study 16397284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 12507747 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5-20 mg daily
Number of subjects: 254
Study 12507747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 11132737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 3.5% (Dex) with 10 microg sufentanil
Number of subjects: 48
Study 11132737 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) with 10 microg sufentanil
Number of subjects: 48
Study 9279217 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil dust control (treatment)
Number of subjects: 20
Study 9279217 — intervention group
Group type: COMPARATOR
Intervention: Traditional swine room (control)
Number of subjects: 20
Study 9279217 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 20
Study 9279217 — intervention group
Group type: COMPARATOR
Intervention: Control room exposure
Number of subjects: 20
Study 9279217 — intervention group
Group type: COMPARATOR
Intervention: Control day
Number of subjects: 20
Study 9279217 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoprovocation tests
Number of subjects: 20
Study 9279217 — intervention group
Group type: COMPARATOR
Intervention: Nasal lavage cytokines
Number of subjects: 20
Study 8364262 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS (electronic medication-event monitoring device)
Number of subjects: 47
Study 8364262 — intervention group
Group type: COMPARATOR
Intervention: Pill counts (control group)
Number of subjects: 47
Study 8364262 — intervention group
Group type: COMPARATOR
Intervention: Control group (pill counts)
Number of subjects: 47
Study 2878088 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B administered intravenously in small doses
Number of subjects: 28
Study 2878088 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 2878088 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B
Number of subjects: 28
Study 29548345 — intervention group
Group type: EXPERIMENTAL
Intervention: Volixibat 20 mg, 40 mg, or 80 mg once daily for 12 days
Number of subjects: 84
Study 29548345 — intervention group
Group type: EXPERIMENTAL
Intervention: Volixibat
Number of subjects: 84
Study 29548345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 27634451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular phrenic nerve block with 10 ml ropivacaine
Number of subjects: 76
Study 27634451 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml saline)
Number of subjects: 76
Study 24661520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol
Number of subjects: 119
Study 24661520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 119
Study 22964540 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-based psychodynamic treatment (IPDT)
Number of subjects: 81
Study 22964540 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavior therapy (ICBT)
Number of subjects: 81
Study 22964540 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 81
Study 19846183 — intervention group
Group type: EXPERIMENTAL
Intervention: Unheated sunflower oil
Number of subjects: 22
Study 19846183 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated sunflower oil
Number of subjects: 22
Study 19846183 — intervention group
Group type: COMPARATOR
Intervention: Cream (CR)
Number of subjects: 22
Study 17630091 — intervention group
Group type: EXPERIMENTAL
Intervention: CASTest scenarios
Number of subjects: 2449
Study 17630091 — intervention group
Group type: COMPARATOR
Intervention: Course centre
Number of subjects: 2449
Study 17630091 — intervention group
Group type: COMPARATOR
Intervention: Professional group
Number of subjects: 2449
Study 17630091 — intervention group
Group type: COMPARATOR
Intervention: Candidate order
Number of subjects: 2449
Study 16267659 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg daily)
Number of subjects: 0
Study 16267659 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR (75 mg daily)
Number of subjects: 0
Study 14728495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent IV infusion pumps with integrated software for decision support (DS)
Number of subjects: 0
Study 14728495 — intervention group
Group type: COMPARATOR
Intervention: Current IV infusion pump systems without intelligent software
Number of subjects: 0
Study 11209540 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin
Number of subjects: 279
Study 11209540 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 279
Study 8647965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 25 to 40 mg/kg daily for 3 months
Number of subjects: 70
Study 8647965 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 70
Study 8647965 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine vs Placebo
Number of subjects: 70
Study 1524279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy or adenotonsillectomy
Number of subjects: 268
Study 1524279 — intervention group
Group type: COMPARATOR
Intervention: Control (non-receipt of surgery)
Number of subjects: 268
Study 6666220 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg sustained release isosorbide dinitrate
Number of subjects: 10
Study 6666220 — intervention group
Group type: COMPARATOR
Intervention: 40 mg isosorbide‐5‐mononitrate
Number of subjects: 10
Study 30717779 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognitive theory-based physical activity intervention (16 weeks, 1 session per week, 90 min each)
Number of subjects: 272
Study 30717779 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognitive theory-based physical activity intervention
Number of subjects: 272
Study 29476613 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (5%, 11%, and 16%)
Number of subjects: 40
Study 29476613 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance
Number of subjects: 40
Study 27028745 — intervention group
Group type: EXPERIMENTAL
Intervention: Kikyo-To (KKT) 5.0 g mixed with jelly
Number of subjects: 2
Study 27028745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (jelly only)
Number of subjects: 2
Study 24561145 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe target lesion calcification
Number of subjects: 6855